New research looks at the factors that speed up and slow down HTA appraisals for rare disease medicines across Europe. Rare diseases drugs have always faced challenges when it comes to HTA approvals, ...

The way healthcare technology assessments (HTAs) are conducted in Europe is changing. In less than a year, all new advanced therapeutic products and oncology drugs will be subject to a mandatory, ...

Entering text into the input field will update the search result below Entering text into the input field will update the search result below ...